Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vaidyanathan, G.
Right arrow Articles by Zalutsky, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vaidyanathan, G.
Right arrow Articles by Zalutsky, M. R.
Clinical Cancer Research Vol. 9, 1868-1876, May 2003
© 2003 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Specific and High-Level Targeting of Radiolabeled Octreotide Analogues to Human Medulloblastoma Xenografts1

Ganesan Vaidyanathan, Henry S. Friedman, Donna J. Affleck, Margaret Schottelius, Hans-Jürgen Wester and Michael R. Zalutsky2

Departments of Radiology [G. V., D. J. A., M. R. Z.] and Pediatrics [H. S. F.], Duke University Medical Center, Durham, North Carolina 27710, and Department of Nuclear Medicine, Technical University of Münich, 81675 Münich, Germany [M. S., H-J. W.]

Purpose: The objective of this study was to determine the feasibility of exploiting the overexpression of somatostatin subtype-2 receptors (sstr2) on human medulloblastoma cells to develop targeted radiodiagnostics and radiotherapeutics for this disease.

Experimental Design: The following radioiodinated peptides were prepared using chloramine-T and evaluated: [131I-Tyr3]octreotide ([131I]TOC), [131I-Tyr3]octreotate ([131I]TOCA), involving substitution of Thr(ol)8 in TOC with Thr8, and glucose-[131I-Tyr3]octreotide ([131I]Gluc-TOC) and glucose-[131I-Tyr3]octreotate ([131I]Gluc-TOCA), prepared by conjugation of glucose to the peptide NH2 terminus. Specific internalization of the peptides by sstr2-expressing AR42J rat pancreatic carcinoma cells in vitro was evaluated in paired-label assays. The tissue distribution of i.v. administered [131I]TOC, [131I]TOCA, [131I]Gluc-TOC, and [131I]Gluc-TOCA was evaluated in athymic mice bearing s.c. D341 Med human medulloblastoma xenografts.

Results: Compared with [125I]TOC, internalized radioiodine levels were higher for the other three peptides. For example, internalized counts were 1.9 ± 0.2, 2.0 ± 0.3, and 5.7 ± 1.9 times higher for [131I]Gluc-TOC, [131I]TOCA, and [131I]Gluc-TOCA after a 3-h incubation, respectively, demonstrating that carbohydration and COOH-terminus modification significantly improved the retention of radioiodine activity in sstr2-expressing tumor cells. COOH-terminus modification significantly increased 131I localization in D341 Med medulloblastoma xenografts {[131I]TOCA, 8.1 ± 2.2% of injected dose/g (% ID/g); [131I]TOC, 3.9 ± 0.5% ID/g at 1 h}, whereas carbohydration of the NH2 terminus resulted in even higher gains in tumor accumulation ([131I]Gluc-TOC, 11.1 ± 1.8% ID/g; [131I]Gluc-TOCA, 21.4 ± 7.3% ID/g). In addition, the three modified peptides exhibited liver activity levels that were less than half those of [131I]TOC. Uptake of the two glucose-peptide conjugates in this human medulloblastoma xenograft was blocked by coinjection of 100 µg of octreotide, demonstrating that it was receptor-specific. Tumor:normal tissue uptake ratios for [131I]Gluc-TOCA generally were higher that those for [131I]Gluc-TOC. At 1 h, tumor:normal tissue ratios for [131I]Gluc-TOCA were 29:1, 15:1, 8:1, 8:1, 240:1, and 82:1 for blood, liver, kidney, spleen, brain, and muscle, respectively.

Conclusions: Our findings suggest that additional investigation of radiolabeled Gluc-TOCA analogues for the imaging and targeted radiotherapy of medulloblastoma is warranted.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
M. Schottelius, T. Poethko, M. Herz, J.-C. Reubi, H. Kessler, M. Schwaiger, and H.-J. Wester
First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission Tomography
Clin. Cancer Res., June 1, 2004; 10(11): 3593 - 3606.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. C. Fruhwald, C. H. Rickert, M. S. O'Dorisio, M. Madsen, M. Warmuth-Metz, G. Khanna, W. Paulus, J. Kuhl, H. Jurgens, P. Schneider, et al.
Somatostatin Receptor Subtype 2 Is Expressed by Supratentorial Primitive Neuroectodermal Tumors of Childhood and Can Be Targeted for Somatostatin Receptor Imaging
Clin. Cancer Res., May 1, 2004; 10(9): 2997 - 3006.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.